Article (Scientific journals)
A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis.
REGINSTER, Jean-Yves; Distel, M.; Bluhmki, E.
1996In British Journal of Rheumatology, 35 (Suppl 1), p. 17-21
Peer Reviewed verified by ORBi
 

Files


Full Text
A double-blind three week study.pdf
Publisher postprint (505.25 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage; Arthritis, Rheumatoid/complications/drug therapy; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Middle Aged; Severity of Illness Index; Thiazines/administration & dosage/adverse effects; Thiazoles/administration & dosage/adverse effects; Treatment Outcome
Abstract :
[en] A multicentre, double-blind, randomized study was conducted in patients with rheumatoid arthritis (RA) in order to compare the efficacy and safety of two different doses of meloxicam, a new preferential cyclooxygenase-2 (COX-2) inhibitor. Four hundred and twenty-three patients were randomized to receive once-daily oral meloxicam 7.5 mg (n = 216) or meloxicam 15 mg (n = 207) for 3 weeks. The Ritchie joint index and pain in the morning were significantly improved versus baseline (P < 0.001) in both groups. There were no significant differences between the effects of each dose with respect to these measures nor with respect to final assessment of global efficacy by the patients. However, the 15 mg dose was associated with a significantly (P < 0.05) better effect on morning stiffness and grip strength. No differences between the doses were observed with regard to the other secondary efficacy parameter (pain at night, body weight and erythrocyte sedimentation rate). Both doses of meloxicam were well tolerated. There were no differences between the doses with respect to global tolerance as assessed by the patient and the patients, 'general condition'. In conclusion, meloxicam at a once-daily dose of either 7.5 or 15 mg is well tolerated and effective in the treatment of patients with RA.
Disciplines :
General & internal medicine
Author, co-author :
REGINSTER, Jean-Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Distel, M.
Bluhmki, E.
Language :
English
Title :
A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis.
Publication date :
1996
Journal title :
British Journal of Rheumatology
ISSN :
0263-7103
Publisher :
Oxford University Press, Oxford, United Kingdom
Volume :
35
Issue :
Suppl 1
Pages :
17-21
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 02 May 2012

Statistics


Number of views
48 (6 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
39
Scopus citations®
without self-citations
36
OpenCitations
 
18

Bibliography


Similar publications



Contact ORBi